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Pivotal Role of Nitric Oxide in the Control of Blood
Pressure After Leptin Administration
Gema Frühbeck
Leptin administration has been shown to increase
renal, adrenal, and lumbar sympathetic nerve activity.
H o w e v e r, this generalized sympathoexcitatory activity
is not always followed by an increase in arterial pres-
sure. The present study tested the hypothesis that lep-
tin induces a release of nitric oxide (NO) that opposes
the pressor effect of sympathoexcitation. The effect of
intravenous administration of leptin (10, 100, and
1,000 µg/kg body wt) or vehicle on blood pressure (BP),
heart rate (HR), and serum nitrite/nitrate concentra-
tions of anesthetized Wistar rats was examined. At 90
min after injection, the three leptin doses tested
increased serum NO concentrations 20.5, 33.1, and
89.5%, respectively (P < 0.001 vs. baseline). The eff e c t
of leptin on NO concentrations was significantly dose-
dependent on linear trend testing (P = 0.0001). In con-
trast, leptin did not change serum nitrite/nitrate con-
centrations of f a / f a rats. Leptin administration to 
Wistar rats under NO synthesis inhibition (N - n i t r o -L-
arginine methyl ester [L-NAME]) produced a statisti-
cally significant increase (P < 0.05) in both systolic BP
and mean arterial pressure as well as in HR 
(P < 0.01). Injection of leptin into rats with pharmaco-
logically induced ganglionic blockade (chlorison-
damine) was followed by a decrease in BP and HR to val-
ues significantly lower (P < 0.01) than those observed
with chlorisondamine treatment alone. The leptin-
induced hypotension observed in the setting of gan-
glionic blockade was blocked by L-NAME. These findings
raise the possibility that the leptin-induced release of
NO may contribute to the homeostasis of BP. D i a b e t e s
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Obesity is associated with an increased incidenceof hypertension and cardiovascular mortality(1–3). However, the mechanisms that link obesitywith altered renal function and high blood pres-
sure (BP) have not been fully elucidated. The adipocyte-
derived hormone leptin has been suggested to be implicated
in obesity-related hypertension (4). Intracerebroventricular
as well as chronic intravenous administration of leptin have
been shown to increase both mean arterial pressure (MAP)
and heart rate (HR) (5–7). However, some studies have
reported that MAP and HR were not changed by acute leptin
infusion (7–9).
Because leptin binding sites have been found in brain
regions that are also important in cardiovascular control
(10), there is reason to suspect that leptin may affect car-
diovascular function through its effects on the central nervous
system (CNS). This possibility is supported by the observa-
tion that leptin administration increases sympathetic nerve
activity to kidneys, adrenals, and brown adipose tissue (BAT )
(5,8). However, leptin has also been shown to cause natri-
uresis and diuresis after bolus intravenous infusion (9). Thus,
leptin may be influencing different regulatory pathways that
have opposite effects on BP control.
R e c e n t l y, it has been reported that the functional leptin
receptor OB-Rb is expressed in endothelial cells and that it
is functionally competent (11). This provides evidence that the
endothelium is a target for leptin action. The vascular
endothelium is known to play a critical role in BP home-
ostasis, in part by its ability to produce potent vasoactive fac-
tors, principal among these being the vasodilator nitric oxide
(NO) (12). The aim of this study, therefore, was to assess the
possible role of NO in the leptin-induced effects on BP regu-
lation in Wistar normotensive rats. Several doses of leptin
were used, and serum nitrite/nitrate concentrations were
measured to delineate a concentration-response relation-
ship. Pretreatment with N - n i t r o -L-arginine methyl ester 
(L-NAME) and chlorisondamine was also performed to study
the effects of leptin on BP under NO synthesis inhibition and
acute ganglionic blockade, respectively. In addition, the
effects of leptin on BP, HR, and serum nitrite/nitrate con-
centrations were examined in obese Zucker rats, which have
a mutation in the leptin receptor gene.
RESEARCH DESIGN AND METHODS
Animals and surgical instrumentation. The animals used in this study were
3-month-old male Wistar and obese Zucker (f a / f a) rats (Harlan, Bicester, Oxon,
U.K.). All experimental procedures conformed to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
Animals were anesthetized with an intraperitoneal injection of sodium pen-
tobarbital (50 mg/kg body wt) and received an intramuscular prophylactic dose
of penicillin G (20,000 U) before surgery. The trachea was cannulated to minimize
respiratory difficulties. A small incision was made in the groin for placing a can-
nula in the femoral vein for drug infusion and blood sampling. A catheter was
inserted in the femoral artery for measurement of arterial pressure. The catheter
was filled with heparinized saline (1,000 U/ml). Maintenance of anesthesia was
achieved with intravenous chloralose (25 mg · kg– 1 · h– 1). Rats were prepared for
cardiovascular recording and were allowed to stabilize on a pad heated to main-
tain the body temperature at 37.5 ± 0.5°C.
Study design. Four separate groups of Wistar rats (n = 8 per group) received intra-
venously one of three doses of leptin or vehicle in a bolus injection. The leptin
doses tested were 10, 100, and 1,000 µg/kg body wt. Leptin was dissolved in
phosphate-buffered 0.9% saline, which was used as the control infusion. The
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possible effect of the bacterial lipopolysaccharide present in the recombinant
mouse leptin on hemodynamic and sympathetic parameters has already been
tested and excluded by Haynes et al. (8).
The effects of administration of a physiological dose of leptin (100 µg/kg) were
examined in four additional experimental groups of Wistar rats with NO synthase
(NOS) inhibition or ganglionic blockade. NOS was blocked with a single intra-
venous bolus injection (30 mg/kg, n = 16) of L-NAME, since it has been reported
to evoke in rats a maximal increase of BP, which reaches a plateau in 6 min (13).
At 10 min after L-NAME administration, when steady pressure values had been
reached, animals received either saline (0.9%, n = 8) or leptin (100 µg/kg, n = 8).
Pretreatment with the ganglion-blocking agent chlorisondamine (30 mg/kg i.v., 
n = 16) was followed by a bolus intravenous injection of either saline (0.9%, 
n = 8) or leptin (100 µg/kg, n = 8). Chlorisondamine was chosen because it is
known to produce a complete and irreversible ganglionic blockade (14). Ve h i c l e
and leptin were injected 10 min after the administration of chlorisondamine, at
which time steady levels of BP had been achieved. In a subset of rats, the effect
of L-NAME administration (30 mg/kg i.v., n = 5) on the leptin-induced changes in
BP was studied in the setting of acute ganglionic blockade.
To establish that the effects of leptin on NO release are mediated through lep-
tin receptors, obese f a / f a rats, which lack functional leptin receptors, were injected
with the highest leptin dose previously used (1,000 µg/kg i.v., n = 5). To ensure that
the f a / f a rat is able to release NO in response to other agents, sodium nitroprusside
(4 µg/kg i.v., n = 5), a known NO donor, was tested as a positive control.
Hemodynamic recording, blood sampling, and NO determination. A r t e r i a l
pressure was measured in anesthetized rats via a pressure transducer (Statham
P23AA; Oxnard, CA) connected to a polygraph (Beckman R511A; Fullerton, CA).
Baseline measurements of arterial BP and HR were made for 5 min on three occa-
sions. A blood sample was obtained for analysis of basal serum NO concentration.
At 90 min after administration of leptin or vehicle, BP and HR were recorded and
another venous blood sample was collected. The withdrawn blood was transferred
to glass serum separation tubes, allowed to clot at room temperature (22°C), and
centrifuged (1,200g) for 10 min.
NO was determined photometrically in serum by its oxidation products
nitrite and nitrate using a colorimetric assay (Boehringer Mannheim,
Mannheim, Germany). As described by the manufacturer, NO is detected in bio-
logical fluids via nitrite. The nitrate present in samples is reduced to nitrite by
reduced nicotinamide adenine dinucleotide phosphate in the presence of the
enzyme nitrate reductase (15). The nitrite formed reacts with sulfanilamide and
N-(1-naphtyl)-ethyl-enediamine dihydrochloride to give a red-violet diazo dye.
Finally, the diazo dye is measured based on its absorbance at 550 nm using a
microtiter plate reader.
D r u g s . Recombinant murine leptin was purchased from PeproTech (London,
U.K.). The OB protein showed more than 95% purity, as evidenced by SDS-PA G E
and high-performance liquid chromatography analyses. L-NAME and sodium
nitroprusside were obtained from Sigma (St. Louis, MO). Chlorisondamine was
acquired from Ciba-Geigy (Basel, Switzerland). All drugs were made fresh on the
day of the experiment, and all solutions were infused through a Millipore filter 
(22 µm, Cathivex; Bedford, MA).
Data analysis. Results are expressed as means ± SE. BP and HR values from the
three separate baseline measurements did not differ significantly for any param-
eter and were therefore averaged for each animal. Basal values in the control and
leptin-treated rats were compared by two-tailed unpaired S t u d e n t ’s t test, and
changes from baseline were analyzed by two-tailed paired S t u d e n t ’s t test. Dif-
ferences between leptin-treated and control animals were assessed using a
repeated measures analysis of variance (ANOVA), with statistical testing by
S c h e f f e ’s F test. Dose-dependency was tested by a factorial ANOVA using linear
trend testing. Analyses were performed using the StatView 4.01 Non-FPU (Aba-
cus Concepts, 1992–1993) statistical package for Apple Macintosh computers. A
value of P < 0.05 was considered statistically signific a n t .
R E S U LT S
E ffects of leptin doses on hemodynamics and serum
n i t r i t e / n i t r a t e . No differences in baseline systolic or dias-
tolic arterial pressure or HR were observed between rats
treated with saline and those treated with leptin (Table 1).
Arterial pressure did not change significantly in any group
after leptin or saline administration. In the three leptin-
treated groups (10, 100, and 1,000 µg/kg body wt), there was
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TABLE 1
Hemodynamic data obtained from Wistar rats at baseline and 90 min after intravenous administration of saline or leptin
sBP (mmHg) dBP (mmHg) HR (bpm)
S a l i n e
B a s a l 147 ± 6 83 ± 3 371 ± 13
90 min 144 ± 5 82 ± 3 380 ± 8
Leptin (10 µg/kg)
B a s a l 152 ± 5 84 ± 4 384 ± 11
90 min 159 ± 6 86 ± 3 403 ± 5
Leptin (100 µg/kg)
B a s a l 148 ± 9 91 ± 6 388 ± 7
90 min 142 ± 5 95 ± 4 419 ± 10
Leptin (1,000 µg/kg)
B a s a l 158 ± 7 88 ± 7 373 ± 18
90 min 162 ± 5 85 ± 5 426 ± 9
Data are means ± SE (n = 8 per group). No statistically significant differences from baseline were found (Student’s t t e s t ) .
FIG. 1. Dose-response curve showing percentage increase from base-
line in serum nitrite/nitrate concentrations of Wistar rats 90 min
after intravenous injection of 0.9% saline and three doses of leptin.
* * *P < 0.001 vs. baseline by Student’s t test; §P < 0.05, §§§P < 0.001 vs.
saline by ANOVA. Values are means ± SE (n = 8 per group).
a tendency for HR to increase 90 min after drug injection, but
the magnitude of the increase did not reach statistical signi-
ficance (P = 0.066, P = 0.078, P = 0.093, respectively).
It is noteworthy to point out that intravenous administration
of leptin increased serum nitrite/nitrate concentrations, with
an 89.5 ± 12.5% increase in the first 90 min after the 
1,000 µg/kg dose (P < 0.001 vs. saline) (Fig. 1). Lower doses of
leptin produced more modest increases in serum nitrite/nitrate
levels, which were significantly different from baseline (P
< 0.001) and from the saline control (P < 0.05). The effect of lep-
tin on nitrite/nitrate concentrations was significantly dose-
dependent on linear trend testing (P = 0.0001) (Fig. 1).
No statistically significant changes were observed in MAP
and HR between saline- or leptin-treated f a / f a rats (MAP:
118 ± 5 vs. 122 ± 6 mmHg; HR: 372 ± 14 vs. 383 ± 16 bpm,
respectively). Administration of leptin did not alter
nitrite/nitrate concentrations relative to basal values in
Zucker rats (13.8 ± 0.9 vs. 15.3 ± 1.0 µmol/l, respectively). How-
e v e r, injection of sodium nitroprusside into f a / f a rats pro-
duced a statistically significant increase (P < 0.01) in serum
nitrite/nitrate concentrations (21.8 ± 1.1 µmol/l).
E ffects of leptin under NOS inhibition and acute 
ganglionic blockade. As expected, inhibition of NO syn-
thesis produced an increase in both systolic BP (sBP) and
diastolic BP (dBP) in all rats receiving the L-NAME pretreat-
ment (Table 2). At 10 min after L-NAME administration, MAP
was increased and HR was reduced from control levels
before drug injection. In the animals injected with the NOS
i n h i b i t o r, MAP changed from 108 ± 4 to 149 ± 5 mmHg,
whereas HR decreased from 379 ± 12 to 341 ± 10 bpm. Lep-
tin administration to rats pretreated with L-NAME increased
even more the already high HR and BP values (Table 2, Fig.
2). The statistically significant increase (P < 0.05) in sBP was
accompanied by a clear tendency for an increase in dBP (P
= 0.0841). This resulted in a statistically significant increase
(P < 0.05) in MAP, which changed from 147 ± 7 to 170 
± 7 mmHg.
To observe the hemodynamic effects of leptin in the
absence of simultaneous sympathoactivation, an acute gan-
glionic blockade was pharmacologically induced. Pretreat-
ment with the ganglion-blocking agent chlorisondamine low-
ered both BP and HR in all rats (Table 2, Fig. 2). The initial
hemodynamic parameters for the experimental group receiv-
ing saline were similar to those of animals injected with lep-
tin. Administration of leptin decreased BP and HR to values
s i g n i ficantly lower (P < 0.01) than those observed after gan-
glionic blockade alone. Vehicle injection produced no
changes in arterial pressure and HR over time.
The effect of L-NAME injection in the setting of acute
ganglionic blockade and leptin treatment was also studied
to validate the underlying assumption that the hypotensive
effect of leptin administration observed during ganglionic
blockade is due to NO release. Figure 2 shows that the
inhibitor of NOS blocked the leptin-mediated decrease in BP
(P < 0.01) during pharmacologically induced acute gan-
glionic blockade.
D I S C U S S I O N
The present study shows that leptin increases NO synthesis
in a dose-dependent manner in male normotensive Wistar rats.
Control of BP is achieved, at least in part, by a balance in fac-
tors affecting vasoconstriction and vasodilation. One of the
most important factors controlling ongoing vasoconstriction
is the sympathetic nervous system. It has been clearly shown
that leptin infusion increases sympathetic nerve activity to
B AT, kidney, hindlimb, and adrenal gland (5,8). However, in
some studies as well as in the present study, leptin did not
increase arterial pressure, despite the increase in overall
sympathetic nerve activity (7–9). In this context, Haynes et
al. (8) suggested that leptin may have other effects that off-
set the expected vasoconstrictor effects of increased sym-
pathetic outflo w. The increase in serum NO concentrations
observed in the present study after leptin administration
could oppose the pressor effects of sympathoactivation.
Thus, leptin may influence the balance between hypertensive
and hypotensive mechanisms exerting a homeostatic control
on BP by finely tuning the vascular tone in favor of vaso-
constriction or vasodilation.
This is not the first study to report that leptin acts, at least
in part, via NO. Yu et al. (16) showed that NO mediates lep-
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TABLE 2
Hemodynamic data obtained from Wistar rats under NOS inhibition (L-NAME) or ganglionic blockade (chlorisondamine) at 
baseline and 90 min after intravenous administration of saline or leptin
sBP (mmHg) dBP (mmHg) HR (bpm)
L-NAME (30 mg/kg)
+ S a l i n e
B a s a l 196 ± 8 127 ± 4 345 ± 9
90 min 192 ± 10 121 ± 9 355 ± 11
+Leptin (100 µg/kg)
B a s a l 190 ± 8 125 ± 9 337 ± 11
90 min 222 ± 9* 145 ± 10 398 ± 13†
Chlorisondamine (30 mg/kg)
+ S a l i n e
B a s a l 113 ± 9 52 ± 4 295 ± 14
90 min 117 ± 5 55 ± 3 291 ± 12
+Leptin (100 µg/kg)
B a s a l 119 ± 11 58 ± 2 294 ± 10
90 min 95 ± 8† 44 ± 4† 248 ± 6†
Data are means ± SE (n = 8 per group). *P < 0.05, †P < 0.01 statistically significant differences from baseline (Student’s t test). 
tin-induced luteinizing hormone–releasing hormone and
luteinizing hormone release at the hypothalamic and pituitary
level. The interpretation that leptin-induced NO release is
involved in modulating BP is further strengthened by the
observations made after L-NAME pretreatment as well as
pharmacologically induced ganglionic blockade. When the
i n fluence of leptin on NO release is blocked by NOS inhibi-
tion, the stimulatory effect of leptin on overall sympathetic
nerve traffic clearly overweighs the vasodilatory influ e n c e s ,
leading to even higher BP values than those observed with
NOS blockade only. On the contrary, a marked hypotension
is observed as a result of the effect of leptin on NO synthesis
predominating over the lacking adrenergic-mediated vaso-
constriction during acute ganglionic blockade. Moreover, the
present study also shows that an inhibitor of NOS reverses the
hypotension after leptin administration in the setting of gan-
glionic blockade. Thus, the leptin-induced NO increase may
play a critical role in regulating the hemodynamic adjust-
ments in response to the leptin-mediated sympathoactivation.
R e c e n t l y, it has been shown that leptin increases endothelial
production of NO in isolated aortic rings (17). This effect
was not observed in rings denuded of endothelium or treated
with L-NAME (17).
In Zucker rats—the mutant rats that lack functional leptin
receptors— administration of leptin did not alter sBP or dBP.
This observation is in agreement with the study of Haynes et
al. (8) showing that obese Zucker rats treated with leptin did
not experience changes in BP. These researchers further
showed that, in contrast to their lean littermates, obese
Zucker rats exhibited markedly blunted renal and BAT sym-
pathetic nerve activity responses to leptin. While injection of
leptin into obese Zucker rats was not followed by changes in
nitrite/nitrate concentrations, administration of sodium nitro-
prusside produced an increase in serum nitrite/nitrate levels
relative to basal values in the present study. Thus, the f a / f a
rat is able to release NO in response to sodium nitroprusside,
a known NO donor, but not in response to leptin. Ta k e n
t o g e t h e r, all these facts show that the effects of leptin on BP,
NO release, and sympathetic nerve activation seem to
require functional leptin receptors.
The finding of an increase in serum NO concentrations at
90 min after a single intravenous injection of leptin indicates
that leptin exerts a role of physiological relevance in short-
term cardiovascular regulation. This observation comple-
ments the study of Shek et al. (6) reporting the CNS and
peripheral effects of leptin in long-term BP control. Leptin is
a good example of extreme functional pleiotropy. Originally
i d e n t i fied by its effects on food intake and body weight reg-
ulation, leptin has subsequently been shown to be capable of
stimulating a variety of biological responses in a wide spec-
trum of cell types. As far as BP control is concerned, leptin
increases sympathetic nerve activation (5,8), causes natri-
uresis and diuresis (9), and seems to be involved in endothe-
lial NO release.
There are several potential limitations of this study that
need to be addressed. First, the experiments were performed
by using recombinant mouse leptin in Wistar rats, and the
effects of rat leptin may be different. However, it has been
shown that the nucleotide sequence of the coding region of
rat o b gene is highly homologous to the mouse gene (95% at
the nucleotide level and 96% at the protein level) (18). Also,
murine leptin has been shown to be biologically active in
rats in an experiment (8) similar to this one as well as in other
studies (e.g., 19). Second, because the animals were anes-
thetized, it could be argued that different results would be
obtained under more physiological circumstances. To
address this concern requires performing the same study in
conscious unrestrained rats. Third, the effect on NO was
determined by measuring serum nitrite/nitrate concentra-
tions, which is not a sensitive method for detecting low doses
of NO produced by an activation of endothelial NOS. How-
e v e r, since changes were clearly observed with this method,
it may mean that even more marked differences might have
been obtained with a more sensitive technique.
The present study does not indicate whether the leptin-
induced NO increase observed is due to a direct effect of lep-
tin or secondary to an interaction with other physiological
factors. Interestingly, leptin has been shown to present
striking structural similarities to members of the long-chain
helical cytokine family (20,21), and several investigators
have demonstrated the existence of a cytokine-inducible L-
arginine/NO pathway (22,23). Apart from the direct actions
of NO on vascular smooth muscle, additional roles for NO
in the regulation of cardiovascular functions have been pro-
posed. Several groups have reported an inhibitory effect of
NO on sympathetic outflow in vivo, suggesting a periph-
eral modulation of the sympathetic vasoconstriction by NO
that is independent of the degree of central sympathetic
nerve activity (24–26). Direct evidence for the role of neu-
ropeptide Y (NPY) in sympathetic nerve stimulation–induced
vasoconstriction has also been provided (27). NPY is known
to produce contraction of vascular smooth muscle cells, both
directly and by potentiating the effects of other vasocon-
strictors. Recently, NPY Y1 receptors have been shown to
mediate this response (28). Leptin has been shown to inhibit
906 DIABETES, VOL. 48, APRIL 1999
LEPTIN-INDUCED NITRIC OXIDE INCREASE
FIG. 2. Percent change from baseline in MAP of Wistar rats under NOS
inhibition (L-NAME; 30 mg/kg) or acute ganglionic blockade (chlo-
risondamine; 30 mg/kg). Results represent mean change 90 min after
intravenous injection of vehicle (0.9% saline) or leptin (100 µg/kg).
Values are means ± SE (n = 8 per group). In a subset of rats (n = 5),
the effect of an inhibitor of NOS (L-NAME; 30 mg/kg) was tested in the
setting of ganglionic blockade and leptin pretreatment (chlorison-
damine [30 mg/kg] + leptin [100 µg/kg]). *P < 0.02, **P < 0.01, ***P <
0.001 vs. saline by Student’s t t e s t .
the synthesis and release of NPY (29). Thus, leptin may, in
addition to increasing the concentration of NO, attenuate the
vasoconstrictor effect of NPY. Conversely, the effects of
leptin observed in the present study could be explained as
the effects of an NPY decrease.
Because leptin’s effects on NO synthesis appear to be pro-
tective against the development of high BP, it may be argued
that if the vasculature is resistant to leptin’s actions, it may be
involved in the development and/or maintenance of arterial
hypertension. Therefore, a defect in the leptin system may
contribute to hypertension as well as obesity. The increased
incidence of hypertension observed in obesity may be
explained by a hampered NO-modulation of a compensatory
hypertensive response. This possibility is supported by
findings made in both animal models and humans. It has been
reported that obesity-related hypertension is associated with
attenuated arterial dilation (30). Furthermore, NOS activity
has been shown to be decreased in obese Zucker rats com-
pared with littermate control rats (31), and the JCR:LA cor-
pulent rat shows a defective NO-mediated vascular relax-
ation (32). In humans, an impaired endothelium-derived NO
synthesis in obesity has been shown (33). In addition, an
impaired NO-mediated vasodilation has been reported in
elderly subjects, being that high BP is more commonly asso-
ciated with old age (34). However, it remains unclear to what
extent sympathetic vasoconstriction is actually curtailed by
NO under pathophysiological circumstances and whether
this effect differs among vascular beds.
In summary, this study provides evidence that an intra-
venous bolus injection of leptin increased nitrite/nitrate con-
centrations in a dose-dependent manner in normotensive
Wistar rats. This effect needed functionally competent leptin
receptors, since the leptin-induced increase in nitrite/nitrate
levels could not be replicated in obese Zucker rats, which have
a mutation in the leptin receptor gene. Leptin administra-
tion also increased MAP in L-NAME-treated Wistar rats and
decreased MAP in rats with pharmacologically induced gan-
glionic blockade. Thus, leptin appears to have a balanced
effect on BP with a pressor response attributable to sympa-
thetic activation and a depressor response attributable to
NO release. The present study envisages, for the first time, the
possibility that leptin is involved in the control of vascular
tone by simultaneously producing a neurogenic pressor
action and an opposing NO-mediated depressor effect.
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